Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/175915
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBragado, Paloma-
dc.contributor.authorFernández-Nogueira, Patricia-
dc.contributor.authorCarbó Carbó, Neus-
dc.contributor.authorGascón, Pere-
dc.date.accessioned2021-03-30T14:53:29Z-
dc.date.available2021-03-30T14:53:29Z-
dc.date.issued2020-12-08-
dc.identifier.issn1949-2553-
dc.identifier.urihttps://hdl.handle.net/2445/175915-
dc.description.abstractThe majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].-
dc.format.extent3 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherImpact Journals-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.27829-
dc.relation.ispartofOncotarget, 2020, vol. 11, num. 49, p. 4541-4543-
dc.relation.urihttps://doi.org/10.18632/oncotarget.27829-
dc.rightscc-by (c) Bragado, Paloma et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)-
dc.subject.classificationFibroblasts-
dc.subject.classificationCàncer-
dc.subject.otherFibroblasts-
dc.subject.otherCancer-
dc.titleUnraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec710528-
dc.date.updated2021-03-30T14:53:29Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33346249-
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
710528.pdf1.13 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons